Next Phase Newsletter

A venture capital firm with offices in Canada is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD 0.5 million and USD 5 million. The firm is currently operating out of its second fund in which it has made three investments after making thirteen investments out of its inaugural fund. The firm participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel.

The firm is primarily interested in investing in companies in the digital health sector but will also consider the medical and diagnostic devices sectors that have a digital component to them. The firm is open to all modalities within the digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in development as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology to be revenue generating.

The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat as determined by check size on a case-by-case basis. The firm will participate both as a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm founded in 2020 by experienced investment professionals and headquartered in the USA is currently operating out of its inaugural fund and is actively looking for deal flow. Typical investment size ranges from USD 0.5 million to USD 2 million. Investment strategy at the firm is evolving but currently the firm participates in equity investments only. The firm looks to partner with early-stage companies and is open to global opportunities but will typically focus on opportunities in the United States.

The firm is interested in investing in therapeutics companies, or companies in other sectors that have a therapeutic component. Within therapeutics the firm will consider assets from pre-clinical to pre-IND filing and generally prefers to see some type of proof-of-concept data. Within medical devices and diagnostics, the firm invests in technologies that are pre-commercial and is open to all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will invest in companies throughout all indications including those in orphan diseases.

The firm is open to working with experienced management teams. The firm looks to work with management teams that are ambitious and able to work together and execute well. The firm takes an active role in the companies in which it invests; however, the firm currently only looks to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm launched a healthtech-focused fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in the USA and investing out of their third fund currently makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $15-$50m per company.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A listed pharmaceutical company with $5 Billion of assets under management has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area after 2 decades of arduous efforts. The firm is open to global R&D partnerships and investment opportunities.

The firm has a focused interest in finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An innovative private equity firm and investment fund utilizes the virtual pharma (‘asset-centric’) model and invests in early stage pharmaceutical assets (i.e., small molecules and biologics, including cell and gene therapies), and provides up to $25 million, or more, to fund each project, typically through Phase 2 clinical proof-of-concept, before exiting through sales of successful assets to major pharmaceutical companies. The firm prefers to invest in individual assets through innovative deal structures, and is less likely to make traditional equity investments in companies. The company founders continue to lead development of their asset. Ideal investment candidates have yet to receive significant VC funding, and the firm prefers to invest without typical syndicates. The firm integrates each company’s founders and their asset into a dedicated special purpose vehicle and collaborates closely with them — providing broad and deep drug development expertise and resources to maximize product value. The firm invests in projects around the globe and aims to maintain an ongoing investment portfolio of 15-25 high quality assets.

The firm seeks biopharmaceutical drug assets — small molecules, biologics, and cell or gene therapies. The firm is willing to invest in drug candidates that are up to 12-18 months pre-IND, as well as those that are in, or have completed, Phase I clinical trial(s). Ideal candidates are ‘IND-ready’, patent-protected in all major pharma markets, and represent both potential solutions to major unmet medical needs and significant market potential. The firm is open to all therapeutic areas and indications for which proof-of-concept can be evaluated in early clinical trials, including single asset companies managed by small experienced teams.

The firm is looking to partner with founders and associates with a deep understanding of the science and pharmacology underlying their product, and who are willing to operate in a highly collaborative, virtual and global environment. Such willingness to collaborate is essential because the firm acts as a hands-on investor and partner — contributing its extensive drug development expertise, operational resources and industry connections to each company’s asset to ensure all assets are developed in the most efficient and effective manner, with a particular focus on early development de-risking.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture firm with offices in US and Israel invests in multiple sectors, including the life sciences. The firm invests in pre-seed and seed stage companies; within healthcare, therapeutics, diagnostics and R&D tools companies developing platform technologies. The firm invests early, often acting as the first institutional capital, investing just after the initial stages of product development. The firm generally leads rounds, investing between $.5-5M in rounds no larger than ~$7M. While the firm has to this point invested in US and Israeli companies, it will also consider European and Canadian companies as well.

Within healthcare, the firm is interested in platform technologies in therapeutics and diagnostics/R&D tools. The firm is agnostic to indication and modality, and is looking for companies that have multiple avenues of development to reach the market. Previous investments include companies building CRISPR technologies, post-treatment monitoring, -omics-based drug development, CAR-T and high-throughput screening. The firm does not invest in digital health or medical devices.

The firm acts as a lead investor. Even though they invest early, the firm prefers that the company have at least two full time co-founders before investing. The firm does take a board seat after investing, and is an active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.